Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
58% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.03   Max: 44.56
Current: 0.03

0.03
44.56
Equity to Asset 0.21
MYL's Equity to Asset is ranked lower than
56% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. MYL: 0.21 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.92
Current: 0.21

0.19
0.92
Interest Coverage 3.62
MYL's Interest Coverage is ranked lower than
52% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. MYL: 3.62 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 3.62

0.83
9.19
F-Score: 8
Z-Score: 1.88
M-Score: -2.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.44
MYL's Operating margin (%) is ranked higher than
86% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. MYL: 16.44 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 16.44

2.31
36
Net-margin (%) 9.03
MYL's Net-margin (%) is ranked higher than
77% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. MYL: 9.03 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 9.03

-3.53
30.52
ROE (%) 21.20
MYL's ROE (%) is ranked higher than
96% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYL: 21.20 )
MYL' s 10-Year ROE (%) Range
Min: -6.7   Max: 25.05
Current: 21.2

-6.7
25.05
ROA (%) 4.09
MYL's ROA (%) is ranked higher than
73% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. MYL: 4.09 )
MYL' s 10-Year ROA (%) Range
Min: -1.74   Max: 22.13
Current: 4.09

-1.74
22.13
ROC (Joel Greenblatt) (%) 34.10
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. MYL: 34.10 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.09   Max: 90.88
Current: 34.1

4.09
90.88
Revenue Growth (%) 1.90
MYL's Revenue Growth (%) is ranked higher than
63% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 1.90 )
MYL' s 10-Year Revenue Growth (%) Range
Min: -6.1   Max: 54.5
Current: 1.9

-6.1
54.5
EBITDA Growth (%) 5.90
MYL's EBITDA Growth (%) is ranked higher than
70% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MYL: 5.90 )
MYL' s 10-Year EBITDA Growth (%) Range
Min: -20   Max: 107
Current: 5.9

-20
107
EPS Growth (%) 32.40
MYL's EPS Growth (%) is ranked higher than
89% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. MYL: 32.40 )
MYL' s 10-Year EPS Growth (%) Range
Min: -28.8   Max: 110.4
Current: 32.4

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MYL Guru Trades in Q2 2013

John Hussman 800,000 sh (New)
Paul Tudor Jones 465,100 sh (+1335.49%)
Joel Greenblatt 129,295 sh (+668.47%)
Steven Cohen 1,053,705 sh (+238.21%)
Vanguard Health Care Fund 4,775,700 sh (+14.36%)
Scott Black 378,284 sh (+1.98%)
Louis Moore Bacon 600,000 sh (unchged)
Tom Russo Sold Out
Stanley Druckenmiller Sold Out
John Paulson 12,139,300 sh (-32.83%)
Mario Gabelli 13,000 sh (-35.28%)
Ray Dalio 61,097 sh (-79.15%)
Jim Simons 503,200 sh (-79.77%)
» More
Q3 2013

MYL Guru Trades in Q3 2013

Caxton Associates 200,000 sh (New)
John Paulson 12,139,300 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Jim Simons Sold Out
Ray Dalio Sold Out
Scott Black 359,799 sh (-4.89%)
Paul Tudor Jones 431,700 sh (-7.18%)
John Hussman 454,000 sh (-43.25%)
Steven Cohen 524,317 sh (-50.24%)
Joel Greenblatt 10,695 sh (-91.73%)
» More
Q4 2013

MYL Guru Trades in Q4 2013

David Dreman 1,221 sh (New)
John Paulson 12,139,300 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
Caxton Associates Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 519,430 sh (-0.93%)
Scott Black 307,214 sh (-14.62%)
Joel Greenblatt 7,291 sh (-31.83%)
John Hussman 200,000 sh (-55.95%)
» More
Q1 2014

MYL Guru Trades in Q1 2014

Jim Simons 1,401,474 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Andreas Halvorsen 1,776,108 sh (New)
Paul Tudor Jones 432,717 sh (New)
Louis Moore Bacon 134,160 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Joel Greenblatt Sold Out
David Dreman Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-03-31 Reduce -75%0.47%$42.26 - $57.2 $ 51.397%50000
Scott Black 2014-03-31 Reduce -10.63%0.16%$42.26 - $57.2 $ 51.397%274571
Jean-Marie Eveillard 2014-03-31 New Buy0.09%$42.26 - $57.2 $ 51.396%675428
Joel Greenblatt 2014-03-31 Sold Out 0.01%$42.26 - $57.2 $ 51.396%0
David Dreman 2014-03-31 Sold Out $42.26 - $57.2 $ 51.396%0
John Hussman 2013-12-31 Reduce -55.95%0.53%$37.865 - $44.5 $ 51.3925%200000
Scott Black 2013-12-31 Reduce -14.62%0.23%$37.865 - $44.5 $ 51.3925%307214
Joel Greenblatt 2013-12-31 Reduce -31.83%$37.865 - $44.5 $ 51.3925%7291
David Dreman 2013-12-31 New Buy$37.865 - $44.5 $ 51.3925%1221
John Hussman 2013-09-30 Reduce -43.25%0.48%$30.37 - $38.95 $ 51.3946%454000
Joel Greenblatt 2013-09-30 Reduce -91.73%0.16%$30.37 - $38.95 $ 51.3946%10695
Ray Dalio 2013-09-30 Sold Out 0.02%$30.37 - $38.95 $ 51.3946%0
John Hussman 2013-06-30 New Buy1.1%$27.96 - $31.87 $ 51.3972%800000
John Paulson 2013-06-30 Reduce -32.83%0.98%$27.96 - $31.87 $ 51.3972%12139300
Joel Greenblatt 2013-06-30 Add 668.47%0.15%$27.96 - $31.87 $ 51.3972%129295
Ray Dalio 2013-06-30 Reduce -79.15%0.06%$27.96 - $31.87 $ 51.3972%61097
Mario Gabelli 2013-06-30 Reduce -35.28%$27.96 - $31.87 $ 51.3972%13000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Mylan Inc

Scott Black’s Top First Quarter Holdings
Scott Black is the chairman, president, chief investment officer and founder of Boston-based Delphi Management, and is often featured in Barron’s. Delphi Management’s investment philosophy states that they “only invest in companies that meet our internally developed set of rigorous quantitative criteria.” The fund also only invests in equity securities of US-listed companies, and takes only long positions. Read more...
S&P Winners Broadly Held by Billionaires
Over 12 months, FLIR Systems Inc. (FLIR) is up 61%, Mylan Inc. (MYL) is up 64% and Nabors Industries Ltd. (NBR) is up 24%, making them three of the biggest winners in the S&P 500. Here’s a company update about the top billionaire stakeholders, as of June 30, 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.30
MYL's P/E(ttm) is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.50 vs. MYL: 32.30 )
MYL' s 10-Year P/E(ttm) Range
Min: 11.01   Max: 113.27
Current: 32.3

11.01
113.27
P/B 6.10
MYL's P/B is ranked higher than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYL: 6.10 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 7.02
Current: 6.1

0.64
7.02
P/S 2.90
MYL's P/S is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MYL: 2.90 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 5.69
Current: 2.9

0.41
5.69
PFCF 25.40
MYL's PFCF is ranked higher than
90% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 25.40 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 82
Current: 25.4

8.81
82
EV-to-EBIT 23.43
MYL's EV-to-EBIT is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. MYL: 23.43 )
MYL' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 28.8
Current: 23.43

6.6
28.8
PEG 4.50
MYL's PEG is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 356.67 vs. MYL: 4.50 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 4.5

0.37
11.64
Shiller P/E 50.90
MYL's Shiller P/E is ranked higher than
81% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 50.90 )
MYL' s 10-Year Shiller P/E Range
Min: 10.98   Max: 701
Current: 50.9

10.98
701
Current Ratio 1.64
MYL's Current Ratio is ranked higher than
60% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MYL: 1.64 )
MYL' s 10-Year Current Ratio Range
Min: 1.39   Max: 8.52
Current: 1.64

1.39
8.52
Quick Ratio 0.98
MYL's Quick Ratio is ranked higher than
54% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. MYL: 0.98 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.76
Current: 0.98

0.85
6.76

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.60
MYL's Price/DCF (Projected) is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 2.60 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.51
Current: 2.6

0.62
2.51
Price/Median PS Value 1.60
MYL's Price/Median PS Value is ranked higher than
62% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. MYL: 1.60 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.74
Current: 1.6

0.36
3.74
Price/Peter Lynch Fair Value 3.70
MYL's Price/Peter Lynch Fair Value is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 3.70 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 10.2
Current: 3.7

0.67
10.2
Earnings Yield (Greenblatt) 4.30
MYL's Earnings Yield (Greenblatt) is ranked higher than
70% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. MYL: 4.30 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15
Current: 4.3

3.5
15
Forward Rate of Return (Yacktman) 10.80
MYL's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MYL: 10.80 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.4   Max: 38.9
Current: 10.8

3.4
38.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MYL.Germany
Mylan, Inc. was incorporated in Pennsylvania in 1970. The Company and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients. The Company has two reportable segments, the Generics Segment and the Specialty Segment. The principal markets for the Generics Segment products are proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies primarily within the United States and Canada, Europe, the Middle East and Africa, Australia, Japan, India and New Zealand. The Generics Segment also develops active pharmaceutical ingredients with non-infringing processes to partner with generic manufacturers in regulated markets such as the U.S. and European Union at market formation. The principal market for the Specialty Segment products is pharmaceutical wholesalers and distributors, pharmacies and health care institutions primarily in the U.S. The specialty business is engaged respiratory, allergy and psychiatric therapies. The Company's active pharmaceutical ingredient business is conducted through Mylan Laboratories Limited. It also manufactures and supplies low cost, high quality active pharmaceutical ingredients for its own products and pipeline, as well as for third parties. During 2012, it completed more than 690 global country level product submissions, which included 88 in North America, 375 in EMEA and 229 in Asia Pacific. The Company's EPIPEN Auto-Injector is the number one prescribed epinephrine auto-injector. It markets a global portfolio of approximately 1,100 different products covering a vast array of therapeutic categories. In the U.S., the company has products portfolio consisting of approximately 365 products, of which approximately 310 are in capsule or tablet form in an aggregate of approximately 880 dosage strengths. Included in these totals are approximately 40 extended-release products in a total of approximately 105 dosage strengths.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Scott Black’s Top First Quarter Holdings Apr 23 2014 
Should You Buy Actavis? Mar 18 2014 
Scott Black’s Top Five Stocks at Year End Jan 09 2014 
Scott Black’s Top Five Third Quarter Holdings Oct 22 2013 
S&P Winners Broadly Held by Billionaires Oct 06 2013 
Weekly CEO Sells Highlight: Workday Inc., Kirby Corp., Mylan Inc., Infinera Corporation Sep 09 2013 
Three Stocks for a Recovering Europe Jul 29 2013 
comment on MYL Jan 03 2013 
comment on MYL Jan 01 2013 
Weekly Top Insider Sells: FIS, MYL, LMCA Dec 24 2012 

More From Our Partners
Will Congress Scuttle the AbbVie-Shire Merger? Jul 18 2014 - FOXBUSINESS

More From Other Websites
[video] Don't Expect Tax Inversion Fever to Break Anytime Soon Jul 22 2014
Hatch’s Conditions on Inversion Law Show Partisan Split Jul 22 2014
Tax inversions allow firms to avoid state taxes Jul 21 2014
Why Abbott's Stake In Mylan Will Be Value-Creative Jul 21 2014
US companies sit at a crossroads on tax inversions Jul 19 2014
Here’s the sad truth about tax-‘inversion’ deals Jul 18 2014
AbbVie To Buy Shire For $54 Billion In Biggest Inversion Deal Ever Jul 18 2014
Mylan, Clear Channel, Aereo, Globus: Intellectual Property Jul 17 2014
Hatch Open to Some Near-Term Steps Addressing Inversions Jul 17 2014
Acorda Therapeutics Sues Mylan Over Plan to Copy MS Drug Jul 17 2014
Mylan Wins Permanent Block of Apotex Generic Paxil Sales Jul 17 2014
Mylan Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Apotex; Apotex Can No... Jul 17 2014
Mylan Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Apotex; Apotex Can No... Jul 17 2014
Congress And Tax Inversions: A Wall Streeter's Take On 2014 Jul 16 2014
Abbott, St. Jude Top Views, But Stocks Under Pressure Jul 16 2014
[video] Treasury Secretary Urges Congress to Limit Corporate Inversion Transactions Jul 16 2014
Treasury Urges Halt to Tax Inversion M&A 'Abuse' Jul 16 2014
Slim chances seen for tax 'inversion' clampdown, analysts say Jul 16 2014
Mylan (MYL) Joins the Tax-Inversion Wave Jul 16 2014
Treasury calls on Congress to halt inversion deals Jul 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide